Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
151 hedge funds and large institutions have $1.1B invested in Epizyme, Inc in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 48 increasing their positions, 45 reducing their positions, and 33 closing their positions.
1,347% more call options, than puts
Call options by funds: $30.4M | Put options by funds: $2.1M
7% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 45
6% less funds holding
Funds holding: 160 → 151 (-9)
21% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 33
27% less capital invested
Capital invested by funds: $1.5B → $1.1B (-$405M)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$11.9M |
| 2 |
Morgan Stanley
New York
|
+$10.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.31M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$7.01M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$6.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$32M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$22.3M |
| 3 |
AG
Artal Group
Luxembourg
|
-$11.7M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$11.3M |
| 5 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$9.68M |
EPZM Hedge Fund Activity: Q3 2020 in Review
151 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q3 2020, worth a combined $1.1B — down 27% from $1.5B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of EPZM and 26 opened new positions — a net loss of 7 holders — while 45 trimmed existing stakes and 48 added.
The largest buyer was Palo Alto Investors, adding an estimated $11.9M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $32M sold.
- 151 institutional investors held Epizyme, Inc (EPZM) as of Q3 2020, down from 160 in Q2 2020.
- Funds reported $1.1B of Epizyme, Inc stock for Q3 2020, down 27% quarter-over-quarter.
- 26 funds opened new Epizyme, Inc positions in Q3 2020 and 33 closed out, a net change of -7 holders.
- The largest Epizyme, Inc buyer in Q3 2020 was Palo Alto Investors, an estimated $11.9M added.
- The largest Epizyme, Inc seller in Q3 2020 was Janus Henderson Group, an estimated $32M sold.
Based on aggregated 13F filings for Q3 2020.